Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WorldSymposium

COLUMBUS, OHIO –  Forge Biologics, a genetic medicines development and manufacturing organization, announced today that Maria Escolar, M.D., Chief Medical Officer, will present updated data from the RESKUE Phase 1/2 clinical trialA clinical trial is research designed to understand the safety and efficacy of a drug, biologic or device.  There are 4 phases to most clinical trials from Phase 1 that seeks to answer safety concern for FBX-101, the Company’s novel AAV gene therapyA type of therapy that offers hope and promise for a cure for many genetic disorders.  A working copy of the gene replaces the non-working copy of the gene. Gene therapy is at the forefront of many for the treatment of patients with Krabbe disease, during the 19th Annual WORLDSymposium being held February 22-26, 2023, in Orlando, Florida.  Forge has also dosed the first FBX-101 subject in the REKLAIM Phase 1b clinical trial at the University of Michigan Medical Center.

Link to Full Release